ImCheck to Present Data Demonstrating Activation of the Anti-Tumor Immune Response of Gamma9 Delta2 T Cells in Cancer Patients from the Ongoing Phase I/IIa EVICTION Trial at the AACR Annual Meeting 2021

|   Science & Medicine

ImCheck Therapeutics today announced that it will present  clinical data from the ongoing EVICTION Phase I/IIa clinical trial evaluating ICT01, a first-in-class gamma9 delta2 (γ9δ2) T cell-activating monoclonal antibody, in patients with advanced, relapsed/refractory cancers in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021. The conference will take place virtually from April 10 to April 15, 2021, and abstracts will be available online starting April 9. The presentation will provide a significant update on the EVICTION data presented at the SITC 2020 Annual Meeting.

“The AACR Annual Meeting covers the latest advances across the spectrum of cancer research and clinical development and we are excited to share new data on the anti-tumor immune responses from our ongoing EVICTION trial,”said  Paul Frohna, MD, PhD, Chief Medical Officer at ImCheck Therapeutics. “We are thankful for and encouraged by the progress the investigators and their trial teams have achieved in continuing to enroll patients despite the pandemic.”

Details of the oral presentation are:

Abstract Title: “Activation of the anti-tumor immune response of γ9δ2 T cells in patients with solid or hematologic malignancies with ICT01, a first-in-class, monoclonal antibody targeting Butyrophilin 3A: The EVICTION study”
Session Title: Clinical Trials with Novel Immunooncology Strategies
Presentation Number: CT034
Authors: Aurélien Marabelle, Christiane Jungels, Johann de Bono, Norbert Vey, Martin Wermke, Elena Garralda, Steven Le Gouill, Patricia LoRusso, Aude De Gassart, Patrick Brune, Emmanuel Valentin, Marina Iché, Daniel Olive, Paul A. Frohna
Date/Time: Apr 11, 2021 at 4:00 PM - 5:45 PM ET